Action of sobrerol on mucociliary transport.
Some pharmacological properties of Sobrerol have been assessed, in frog palate preparation, by measuring the mucociliary transport velocity due to mucus samples obtained for patients suffering from chronic bronchial inflammatory diseases characterized by dense bronchial secretions. The patients were studied before and after 4 days of treatment with Sobrerol, 600 mg per day per os. The significant increase in the relative ratio of mucociliary transport of mucus of treated patients, together with evidence coming from previous experiments, indicates that this drug is capable of modifying rheological properties of bronchial secretions, in such patients, through an "in-vivo' muco-regulating activity, thus facilitating mucociliary clearance.
D000328:Adult; D000368:Aged; D000818:Animals; D001692:Biological Transport; D001987:Bronchiectasis / Q000378:metabolism; D001991:Bronchitis / Q000378:metabolism; D002923:Cilia / Q000502:physiology*; D005100:Expectorants / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009093:Mucus / Q000378:metabolism*; D010159:Palate / Q000502:physiology; D011898:Ranidae; D012212:Rheology; D013729:Terpenes / Q000494:pharmacology*; D013997:Time Factors
D005100:Expectorants; D013729:Terpenes; C003316:sobrerol